The study reports the synthesis and antioxidant capability of six novel 10,11-dihydro-5H-dibenzo[b,f]azepine linked 1,2,3-triazoles 6(a–f), synthesized in good yield using copper (II)-catalyzed azide-alkyne 1,3- dipolar cycloaddition reaction (Click Chemistry) under ultrasonication. The alkyne of 10,11-dihydro-5H-dibenzo[b,f]azepine has been prepared and confirmed to have monoclinic geometry using single crystal XRD. All the synthesized compounds are fully characterized using 1H and 13C-NMR, IR, and HRMS. The new compounds 6(a-f) were studied for in vitro DPPH and FRAP antioxidant assay, as well as their ability to inhibit xanthine oxidase enzyme. Compound 6d showed minimum IC50 values of 3.58 ±1.5 µg/ml and 58.66±3 µM for DPPH and FRAP inhibitory effect respectively. The HAT (hydrogen atom transfer) mechanism for DPPH activity and SET (single electron transfer) mechanism for FRAP activity of compound 6d, has been studied through a DFT study on B3LYP hybrid functional at 6-31+G(d,p) basis set. The bond dissociation enthalpy and ionization potential of 6d are 77.01 kcal/mol and 162.59 kcal/mol respectively, proving it to be an excellent antioxidant. Being the best antioxidant 6d has been further used for in vitro inhibition study on xanthine oxidase enzyme isolated from buttermilk. 6d derivative has an IC50 value of 4.93±2 µg/ml much lesser than the standard drug Allopurinol, having an IC50 value of 10.29±1 µg/ml. The molecular docking study is performed on 6(a-f) for XO protein PDBID:1FIQ. All compounds showed effective binding with XO enzyme and the best lead 6d showed a maximum binding energy value of -10.0 kcal/mol. A molecular dynamic simulation study of 100 ns further proved the stability of enzyme 6d complex in the biological system.